SEC Form 4 · accession 0001562180-18-003485
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M. Hindman
Director
Period of report
Aug 1, 2018
Accepted (ET)
Aug 3, 2018 · 5:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F1 | $15.15 | Aug 1, 2018 | A | 20,000 | A | — | Aug 1, 2028 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The option vests with respect to 1/36th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.